|

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

RECRUITINGPhase 2Sponsored by Hospital Universitario Dr. Jose E. Gonzalez
Actively Recruiting
PhasePhase 2
SponsorHospital Universitario Dr. Jose E. Gonzalez
Started2026-02
Est. completion2027-09
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07451652

Summary

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
* ECOG 0-2
* Women of reproductive age who agree on getting a contraceptive method
* Subjects who fulfill Lugano´s criteria for disease activity
* Subjects who voluntarily accept to participate in this study

Exclusion Criteria:

* Active bacterial, viral or fungal infection
* Subjects who have already received an autologous o allogeneic stem cell transplantation
* Subjects with other active neoplasias
* Subjects with end-stage failure

Conditions2

CancerRelapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions3

EpcoritamabGemcitabine (1000 mg/m2)Oxaliplatin

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.